Skip to content

US · 21 CFR

21 CFR Part 212

Current Good Manufacturing Practice for Positron Emission Tomography Drugs

eCFR, up to date as of 2026-11-12

Table of contents

  1. 212.1What are the meanings of the technical terms used in these regulations?
  2. 212.2What is current good manufacturing practice for PET drugs?
  3. 212.5To what drugs do the regulations in this part apply?
  4. 212.10What personnel and resources must I have?
  5. 212.20What activities must I perform to ensure drug quality?
  6. 212.30What requirements must my facilities and equipment meet?
  7. 212.40How must I control the components I use to produce PET drugs and the containers and closures I package them in?
  8. 212.50What production and process controls must I have?
  9. 212.60What requirements apply to the laboratories where I test components, in-process materials, and finished PET drug products?
  10. 212.61What must I do to ensure the stability of my PET drug products through expiry?
  11. 212.70What controls and acceptance criteria must I have for my finished PET drug products?
  12. 212.71What actions must I take if a batch of PET drug product does not conform to specifications?
  13. 212.80What are the requirements associated with labeling and packaging PET drug products?
  14. 212.90What actions must I take to control the distribution of PET drug products?
  15. 212.100What do I do if I receive a complaint about a PET drug product produced at my facility?
  16. 212.110How must I maintain records of my production of PET drugs?
Cover page and contents (original)

Authority:21 U.S.C. 321, 351, 352, 355, 371, 374; Sec. 121, Pub. L. 105-115, 111 Stat. 2296.

Source:74 FR 65431, Dec. 10, 2009, unless otherwise noted.

Source: U.S. Office of the Federal Register / GPO — eCFR · U.S. federal government work — public domain (17 U.S.C. §105). eCFR is an editorial compilation, not an official legal edition of the CFR. · retrieved 2026-11-16

Weekly Newsletter

Get the week's FDA, EU and MFDS inspection findings

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Confirm by email to start · Unsubscribe any time